Amphastar Pharmaceuticals Advances Governance and Shareholder Value
Company Announcements

Amphastar Pharmaceuticals Advances Governance and Shareholder Value

Amphastar Pharmaceuticals (AMPH) has shared an update.

Amphastar Pharmaceuticals, Inc.’s stockholders made significant decisions at the 2024 Annual Meeting, including the approval of an amended 2015 Equity Incentive Plan and the election of four Class II directors. Additionally, Ernst & Young LLP was ratified as the independent accounting firm for the upcoming fiscal year, and executive officer compensation received approval in an advisory vote. Further bolstering investor confidence, the company announced a $50 million expansion to its share buyback program, aimed at mitigating equity compensation dilution and enhancing shareholder value.

See more data about AMPH stock on TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskAmphastar Pharmaceuticals Reports Strong Q3 2024 Results
Austin AngeloAMPH Earnings this Week: How Will it Perform?
TheFlyAmphastar price target lowered to $66 from $71 at Piper Sandler
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App